VisiRose Introduces Revolutionary Therapy for Severe Eye Infections
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals
KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites.
RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular therapy that may be safe, effective, and cost-efficient. The treatment has shown rapid infection resolution and improved patient outcomes in clinical trials across the U.S., India, Brazil, and Mexico.
"RB PDAT is a revolutionary, non-invasive treatment showing remarkable promise for patients with severe infectious keratitis. This innovative therapy harnesses the power of light to combat infection and offers new hope for preserving vision," said Jean-Marie Parel, IngETS-G, Ph.D., FAIMBE, FARVO, Director and co-founder of the Ophthalmic Biophysics Center at BPEI.
Guillermo Amescua, M.D., Professor of Clinical Ophthalmology, Medical Director of the Ocular Microbiology Laboratory, and a board-certified ophthalmologist at BPEI added, "VisiRose is crucial for translating the innovation of RB PDAT from the laboratory to a widely accessible treatment, ultimately benefiting countless patients worldwide."
"VisiRose is the bridge that connects innovation with impact. It enables us to bring the hope of RB PDAT to patients who desperately need it, transforming lives and shaping the future of eye care," said Ed Pershing, Chairman of the Board of Directors of VisiRose and Provectus.
Dominic Rodrigues, Acting CEO of VisiRose added, "RB PDAT offers a beacon of hope for patients facing the threat of vision loss from infectious keratitis. This innovative therapy, with its targeted action and dual benefits, represents a significant advancement in eye care, paving the way for a brighter future for those struggling with this challenging condition."
In more than 500 patients, RB PDAT has shown promising results in treating severe eye infections where traditional therapies have failed. VisiRose is poised to address a significant gap in the $60 billion global ophthalmic market, focusing on regions and populations impacted by rising AMR and the lack of access to effective treatments.
About VisiRose
VisiRose is a newly launched, clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine's Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center's innovative ocular research using Provectus's bioactive synthetic small molecule Rose Bengal Sodium (RBS). For more information, please visit: https://visirose.com.
About Bascom Palmer Eye Institute
The Bascom Palmer Eye Institute, part of the University of Miami Health System, is consistently ranked #1 in ophthalmology in the U.S. by U.S. News & World Report. Known for its cutting-edge research and clinical excellence, Bascom Palmer provides world-class care across all ophthalmic subspecialties and is at the forefront of developing innovative treatments for eye diseases. With a commitment to advancing both patient care and medical research, it is recognized globally as a leader in ophthalmology. For more information, please visit: https://umiamihealth.org/en/bascom-palmer-eye-institute.
About Provectus Biopharmaceuticals
Provectus Biopharmaceuticals (OTCQB: PVCT) is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company's lead molecule is named Rose Bengal Sodium. Provectus's drug platform includes:
Clinical development programs in oncology, dermatology, and ophthalmology,
In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, and
In vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.
Information about the Company's clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For more information, please visit: www.provectusbio.com.
For Media Inquiries:
VisiRose, Inc.
E: contact@visirose.com
W: visirose.com
Contact:
VisiRose, Inc.
Dominic Rodrigues
Acting Chief Executive Officer
E: rodrigues@visirose.com
SOURCE: VisiRose
View the original press release on accesswire.com
VisiRose
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Veganuary for Pets2.1.2025 14:00:00 CET | Press release
WINCHESTER, GB / ACCESSWIRE / January 2, 2025 / Millions of people try vegan diets each January as part of the global Veganuary campaign. In 2024, roughly 25 million people sought a fresh start for their health and the environment through vegan diets. Yet in the decade since Veganuary was founded in 2014, dogs and cats have been almost entirely excluded. Now however, veterinary Professor Andrew Knight is calling for Veganuary to be extended to pets. Writing in The Conversation, Knight notes that dogs and cats may also experience health benefits associated with vegan diets: "By late 2024, 11 studies in dogs, three in cats, and one systematic review covering both had all demonstrated that dogs and cats thrive on modern vegan or vegetarian diets. Certain health benefits appear consistent, such as a reduction in obesity and of conditions that may be triggered by animal-sourced allergens, like itchy skin and ears and gastrointestinal problems." However, he notes that "all diets, including v
The Bilingual Book Company Launches New, Innovative Bilingual Audiobook App27.12.2024 09:30:00 CET | Press release
The app offers line-by-line translation for bilingual audiobooks, making language learning portable and accessible via a mobile/iOS device for learners of all ages. MISSISSAUGA, ONTARIO / ACCESSWIRE / December 27, 2024 / Language-learning innovator Angeline Pompei now offers an app for The Bilingual Book Company, which offers bilingual audiobooks based on interest-based learning for kids and language students, revolutionizing how listeners experience and learn languages through bilingual books. "Bilingual audiobooks inspire curiosity and empower children to explore their interests independently in two languages," Angeline said. "Now available on the app in addition desktop version, users can listen to and read bilingual audiobooks with line-by-line translation, making language learning accessible and enjoyable for people of all ages." The seamless and engaging app is another milestone for The Bilingual Book Company in providing high-quality bilingual audiobooks for children and languag
Beyond Work Unveils Next-Generation Memory-Augmented AI Agent (MATRIX) for Enterprise Document Intelligence23.12.2024 08:00:00 CET | Press release
Matrix streamlines document processing by cutting manual labor and operational costs, using AI agents in the enterprise. LONDON, GB / ACCESSWIRE / December 23, 2024 / Today, Beyond Work, an enterprise AI company, announced the record-setting results of Matrix, a novel memory-augmented AI framework for automating business document processing. Developed in collaboration with researchers from Penn State University, Oregon State University, and Kuehne+Nagel, one of the world's largest logistics providers, Matrix addresses the complex, time-intensive task of extracting transport references from Universal Business Language (UBL) invoices.MATRIX Results Comparing the success rates of four methods (CoT, Two-agent, Reflexion, Matrix) across GPT-4o-mini and GPT-4o, with Matrix achieving the highest performance. By harnessing an iterative, memory-centric learning strategy, Matrix achieves a 30.3% improvement over chain-of-thought prompting, outperforms a standard Large Language Model agent by 35.
MicroVision Increases Production Capacity to Meet Anticipated Demand19.12.2024 09:20:00 CET | Press release
REDMOND, WA / ACCESSWIRE / December 19, 2024 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced that it has increased production capacity for its MOVIA L sensor to meet anticipated demand from the industrial sector. Building on the relationship with its existing automotive Tier 1 manufacturing partner, MicroVision expects output of MOVIA L sensors for 2025 to significantly increase compared to 2024. The continued acceleration of production capacity throughout 2025 will result in a reduced average cost per sensor, while maintaining a high-quality product suitable for industrial applications. "Securing this production capacity is critical to support high-volume orders from industrial customers, so we feel good closing out the year with this commitment in hand," said Sumit Sharma, Chief Executive Officer. "We are pleased with this scaling, particularly from a cost perspective, and our Tier 1 automotive supplier, ZF, i
TechGALA 2025 - Aichi's First International Startup Conference17.12.2024 22:00:00 CET | Press release
Join us 4-6 February 2025 to discover Aichi's international, vibrant startup ecosystem. NAGOYA, JP / ACCESSWIRE / December 17, 2024 / TechGALA, Nagoya's first major startup event, is fast approaching! From February 4-6 2025, TechGALA will open its doors to share Nagoya's business culture of innovation within a system with the world. Read on for more information about this exciting event! TechGALA will be based mainly out of Chunichi Hall and Conference Center, but events will be held at several other locations around the Sakae and Tsurumai neighborhoods - including Nagoya Innovator's Garage and the new STATION Ai campus. Check out the map below for more details: Almost a hundred speakers will be in attendance, including Professor Emori Seita from Tokyo University's Institute for Future Initiatives, Futurist Peter Swain, Chief Sustainability Officer at Toyota Motor Corporation Yumi Otsuka, and artist/writer/non-architect/drag queen Vivienne Sato. In addition to speakers from the busines
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom